|
|||||
|
|
The impact of risk minimization measures on compliance and prescribing practices of flupirtine in Germany |
|
| Authors: | Sigal Kaplan Birgit Ehlken Xenia Hamann |
| Institution: | 1. Teva Pharmaceutical Industries Ltd, Petach Tikva, Israel;2. IQVIA (formerly IMS Health), Munich, Germany;3. Ratiopharm GmbH (an affiliate of Teva Pharmaceuticals Europe BV), Ulm, Germany |
| Abstract: | |
| Keywords: | |